Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan

Investigational New Drugs

Volumn 26, Issue 3, 2008, Pages 205-213

  Gounder, Murugesan K ^a   Nazar, Ahamed S ^b   Saleem, Ahamed ^a   Pungaliya, Pooja ^a   Kulkarni, Diptee ^a   Versace, Richard ^c   Rubin, Eric H ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

9 nitrocamptothecin; ABCC1; ABCC4; ABCG2; BCRP; BCRP mutant cell lines; Gimatecan; PgP; Topoisomerase I mutant cell lines; Topotecan

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; GIMATECAN; GLYCOPROTEIN P; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 4; RUBITECAN; TOPOTECAN; VINBLASTINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ASSAY; CELL LINE; CELL MUTANT; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE I; DOGS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION; TOPOTECAN; TRANSFECTION;

EID: 42549132292     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9093-0     Document Type: Article

References (29)

1. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Ann Rev Biochem 58:351-375
2. Natelson EA, Giovanella BC, Verschraegen CF, Fehir KM, De Ipolyi PD, Harris N, Sthelin JS (1996) Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann NY Acad Sci 803:224-230
3. Hsiang Y, Lihou M, Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082
4. Reid RJ, Benedetti P, Bjornsti MA (1998) Yeast as a model organism for studying the actions of DNA topoisomerase-targeted drugs. Biochim Biophys Acta 1400:289-300
5. Rubin E, Pantazis P, Bharti A, Toppmeyer D, Giovanella BC, Kufe D (1994) Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J Biol Chem 269:2433-2439
6. Zunino F, Pratesi G (2004) Camptothecins in clinical development. Expert Opin Investig Drugs 13:269-284
7. Li TK, Houghton PJ, Desai SD, Daroui P, Liu AA, Hars ES, Ruchelman AL, LaVoie EJ, Liu LF (2003) Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Res 63:8400-8407
8. Rasheed ZA, Rubin EH (2003) Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 22:7296-7304
9. Tsurutani J, Nitta T, Hirashima T, Komiya T, Uejima H, Tada H, Syunichi N, Tohda A, Fukuoka M, Nakagawa K (2002) Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan. Lung Cancer 35:299-304
10. Ohashi N, Fujiwara Y, Yamaoka N, Katoh O, Satow Y, Yamakido M (1996) No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer. Jpn J Cancer Res 87:1280-1287
11. Takatani H, Oka M, Fukuda M, Narasaki F, Nakano R, Ikeda K, Terashi K, Kinoshita A, Soda H, Kanda T, Schneider E, Kohno S (1997) Gene mutation analysis and quantitation of DNA topoisomerase I in previously untreated non-small cell lung carcinomas. Jpn J Cancer Res 88:160-165
12. Reid RJ, Kauh EA, Bjornsti MA (1997) Camptothecin sensitivity is mediated by the pleiotropic drug resistance network in yeast. J Biol Chem 272:12091-12099
13. De Cesare M, Pratesi G, Perego P, Carenini N, Tinelli S, Merlini L, Penco S, Pisano C, Bucci F, Vesci L, Pace S, Capocasa F, Carminati P, Zunino F (2001) Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res 61:7189-7195
14. Perego P, De Cesare M, De Isabella P, Carenini N, Beggiolin G, Pezzoni G, Palumbo M, Tartaglia L, Pratesi G, Pisano C, Carminati P, Scheffer GL, Zunino F (2001) A novel 7-modified camptothecin analog overcomes BCRP-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res 61:6034-6037
15. Rajendra R, Gounder MK, Saleem A, Schellens JH, Ross DD, Bates SE, Sinko P, Rubin EH (2003) Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res 63:3228-3233
16. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal Biochem 72:248-254
17. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS, Bates SE (2003) Mutations at aminoacid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89:1971-1978
18. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, Scheper RJ, Stewart CF, Schuetz JD (2004) Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 24:7612-7621
19. Tian Q, Zhang J, Tan TM, Chan E, Duan W, Chan SY, Boelsterli UA, Ho PC, Yang H, Bian J-S, Huang M, Zhu Y-Z, Xiong W, Li X, Zhou S (2005) Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm Res 22:1837-1853
20. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemot Y, Okada K (1987) Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84:5565-5569
21. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, Saurbery A (2002) BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16:1443-1447
22. Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K, Nishiwaki Y, Kodama T, Suga M, Ochiai A (2004) Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 10:1691-1697
23. Norris MD, Smith J, Tanabe K, Tobin P, Flemming C, Scheffer GL, Wielinga P, Cohn SL, London WB, Marshall GM, Allen JD, Haber M (2005) Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol Cancer Ther 4:547-553
24. Chrencik JE, Staker BL, Burgin AB, Pourquier P, Pommier Y, Stewart L, Redinbo MR (2004) Mechanisms of camptothecin resistance by human topoisomerase I mutations. J Mol Biol 339:773-784
25. Louvard D (1980) Apical membrane aminopeptidase appears at site of cell-cell contact in cultured kidney epithelial cells. Proc Natl Acad Sci USA 77:4132-4136
26. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC (1988) A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85:4486-4490
27. Bakos E, Evers R, Szakács G, Tusnády GE, Walker E, Szabó K, de Haas M, van Deemter L, Borst P, Varadi A, Sarkadi B (1998) Functional multidrug resistance rotein (MRP1) lacking the N-terminal transmembrane domain. J Biol Chem 273:32167-32175
28. Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LC, Paulusma CC, Oude Elferink RP, Baas F, Schinkel AH, Borst P (1998) Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 101:1310-1319
29. Adachi M, Sampath J, Lan AB, Sun D, Hargrove P, Flatley R, Tatum A, Edwards MZ, Wezeman M, Matherly L, Drake R, Schuetz J (2002) Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. J Biol Chem 277:38998-39004